Ph.D., Chief Scientific Officer, BioMarin Pharmaceutical Inc.
Lon Cardon, PhD is the Chief Scientific Officer at BioMarin Pharmaceutical, a biopharmaceutical company specializing in novel therapies for rare genetic diseases. Lon joined BioMarin in September 2017, following more than 25 years of research in discovering new genes for rare and common diseases and developing approaches to translate those discoveries into medicines. He spent the first half of his career as an academic at the University of Oxford and the Fred Hutchinson Cancer Research Centre. In the latter half of his career he has worked in industry to translate the research findings, primarily at GlaxoSmithKline where he was SVP of Genetics, Target Sciences and Alternative Discovery & Development. Lon was a Wellcome Trust Principal Fellow and an elected Fellow of the UK’s Academy of Medical Sciences and the American Association for the Advancement of Science. He has authored more than 225 scientific publications and 15 books and chapters, mainly focused on genetics methodology and applications to rare and common diseases.